US/UK/Canada

Share

Pick a time period -
Tags ( Active)

ArcticZymes Technologies Strengthens Board with Appointment of Dr. Hanna Pirita Lesch, Supporting Diversification into RNA and Continued Leadership in Cell & Gene Therapy

Tromsø, Norway – 28 May 2026 – ArcticZymes Technologies ASA (OSE: AZT) today announced that, following approval at its Annual General Meeting, Dr. Hanna Pirita Lesch has been elected to the Company’s Board of Directors. Dr. Frank Mathias has been re-elected as Chair, and Petter Dragesund has been re-elected as a Board member. Sharon Brownlow steps down from the Board after a period of valued service.The appointment directly supports the execution of ArcticZymes’ strategy: diversifying into RNA through the build-out of a dedicated RNA enzyme portfolio, while continuing to strengthen the

ArcticZymes Expands acib Collaboration and Joins CAARE Consortium to Advance Viral Vector Bioprocessing

Tromsø, Norway - 28[th] April 2026 – ArcticZymes Technologies (Ticker: “AZT”)  announced its participation as an associated partner in the CAARE (Consortium for Advanced Analytical and Recovery Engineering) project, alongside an expansion of its ongoing research collaboration with the Austrian Centre of Industrial Biotechnology (acib), supported by additional funding through the COMET program.Together, these developments reinforce ArcticZymes’ commitment to advancing downstream processing solutions for bionanoparticles, including viral vectors used in gene therapy, vaccines, and oncology

ArcticZymes Technologies ASA – Capital Markets Day 2026. Scaling a High-Performance Enzyme Platform for Compounding Growth

Stockholm, 6 March 2026: ArcticZymes Technologies ASA (OSE: “AZT”) today hosts its Capital Markets Day 2026 in Stockholm, outlining how the Company is scaling a diversified enzyme platform designed to deliver sustainable growth and long-term value creation.Building on more than 30 years of enzyme expertise, ArcticZymes is positioned to benefit from increasing demand for high-performance enzymes used in molecular diagnostics, research and advanced biomanufacturing. “ArcticZymes is entering its next phase of growth. By strengthening our commercial engine, expanding our enzyme portfolio and

ArcticZymes Technologies ASA: Reminder – Capital Markets Day, 6 March 2026

ArcticZymes Technologies ASA (OSE: "AZT") is pleased to invite investors, analysts, media and other stakeholders to its upcoming Capital Markets Day. The objective of the day is to provide clearer insight into ArcticZymes’ position, ambitions, strategic direction and long‑term value creation framework.Date: 6 March 2026 Venue: Smålandsgatan 17, Stockholm (Sweden) / virtually (details below) Time: Doors open at 08:30 Preliminary agenda: · 0830-0900: Registration and coffee · 0900-0915: Introduction · 0915-1200: Capital Markets Day & Q&A · 1200-1230: Lunch and investor

ArcticZymes Technologies Reports Strong Q4 and FY 2025. Accelerating Sales Growth and Improved Profitability

Tromsø, Norway, February 12, 2026 – ArcticZymes Technologies ASA (OSE: AZT) today reported financial results for the fourth quarter and full year 2025, reflecting accelerating sales growth, improved operating leverage and continued penetration in its core business segments. Following a return to growth in 2025, the Company enters 2026 with strengthened commercial momentum and a robust balance sheet.Q4 2025 Highlights · Total revenue: NOK 34.7 million (Q4 2024: NOK 26.4 million), +31% year-on-year · Sales revenue: NOK 34.1 million (Q4 2024: NOK 24.5 million), +39% year-on-year ·

ArcticZymes Technologies ASA – Invitation to Capital Markets Day 2026

ArcticZymes Technologies ASA invites investors, analysts and other stakeholders to its Capital Markets Day on 6 March 2026, 09:00–12:00 CET (registration and coffee from 08:30).The event will take place at Nordea’s offices, Smålandsgatan 17, Stockholm, Sweden but can also be joined virtually.  Building a Scalable Enzyme Platform At the Capital Markets Day, management will present how ArcticZymes has completed its commercial transformation and is now focused on scaling its enzyme platform across high-growth biomanufacturing and molecular tool markets.  The session will address:

ArcticZymes Technologies ASA: Invitation to presentation of Q4 and FY 2025 results

The Company will host a virtual Q4 and 12M 2025 presentation for investors, analysts and media at 10:00 CET on Thursday, 12 February, 2026.The presentation will be given by CEO, Michael Akoh, CCO, Paul Blackburn and CFO, Børge Sørvoll. The presentation can be followed as a live webcast from Hegnar TV on https://qcnl.tv/p/XRgPIoZrlRfhnjAmevVbeQ  or www.arcticzymes.com. It will be possible to post questions through the webcast console. The company is also pleased to announce it will host a Capital Markets Day Friday 6th March from 0900-1200, in Stockholm. More information will be

ArcticZymes Technologies Completes Share Buyback to Support Employee Share Purchase Program

Tromsø, Norway, November 28th, 2025 - Reference is made to the stock exchange announcement published by ArcticZymes Technologies ASA (the "Company", OSE: AZT) on 25 November 2025 announcing the initiation of a share buyback program pursuant to the authorization granted by the Annual General Meeting held on 27 May 2025.The share buyback program has now been completed. From and including 25 November 2025 to and including 28 November 2025, the Company has purchased a total of 31,365 own shares at an average price of NOK 22.5037 per share. Please see the attached table for further details.

ArcticZymes Technologies Reports Q3 2025 Results: Continued Growth Momentum and Strengthened Profitability

Tromsø, Norway, November 6, 2025 – ArcticZymes Technologies (OSE: AZT) today announced its financial results for the third quarter of 2025, reporting strong topline growth and solid operational performance.Total revenues reached NOK 29.8 million, an increase of 24% year-over-year, driven by robust performance across both Biomanufacturing and Molecular Tools segments. A significant milestone following the end of the quarter was the signing of an exclusive European partnership agreement with Brenntag, expanding ArcticZymes’ reach in the biomanufacturing market for advanced therapies. Key

ArcticZymes Technologies Reports Q2 and H1 2025 Results: Biomanufacturing Growth Accelerates as Customer centric Strategy Gains Momentum

Tromsø, Norway, August 14, 2025 – ArcticZymes Technologies (OSE: AZT) today announced its financial results for the second quarter of 2025, highlighting progress in the Company’s commercial transformation. Total revenues reached NOK 28.9 million, up 5% year-over-year, led by strong 52% growth in the Biomanufacturing segment which contributed NOK 18.1 million. The quarter also marked a strategic milestone with the on-time launch of GMP-grade M-SAN HQ, a product developed in direct response to customer needs. M-SAN HQ GMP enables broader integration into viral vector manufacturing and

ArcticZymes Technologies AS - Mandatory notification of trade

Marit Sjo Lorentzen, VP Operations has on 3 June purchased 3.400 shares in ArcticZymes Technoloiges ASA for NOK 16.00 per share. Following this transaction holds Mrs. Lorentzen 28.731 shares and 135,000 options in the company.This information is subject to the disclosure requirements in articles 19 of the Regulation EU 596/2014 (the EU Market Abuse Regulation) and section 5-12 of the Norwegian Securities Trading Act. For additional information, please contactBørge SørvollCFO+4795290187ir@arcticzymes.com

ArcticZymes and Austrian Centre of Industrial Biotechnology Extend Collaborative Research on use of Salt-Active Nucleases for Bionanoparticle Purification

Tromsø, Norway, May 28th, 2025 – ArcticZymes Technologies ASA (OSE: AZT), in collaboration with the Austrian Centre of Industrial Biotechnology (acib), has extended their joint research partnership for another three years, focusing on delivering significantly enhanced purification methods for bionanoparticles (BNPs), critical for safer, more effective gene therapies, vaccines, and cancer treatments.The ongoing phase of the project, which began in April 2024, demonstrated that focusing on the removal of chromatin rather than accessible forms of DNA, is essential for improved purification of

ArcticZymes Technologies ASA - Minutes form Annual General Meeting 2025

(Tromsø 27. May 2025) The Annual General Meeting of ArcticZymes Technologies ASA (OSE:AZT) was held today, 27. May 2025 as a physical meeting with opportunity for virtual participation.Attached to this announcement are the minutes of the Annual General Meeting in Norwegian and an English translation. All items on the agenda were adopted as proposed. For further information, please contact:Børge SørvollCFO+47 952 90187borge.sorvoll@arcticzymes.com This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act.

ArcticZymes Technologies announces Q4 2024 Financial results

Tromsø, Norway, February 13th, 2025 – ArcticZymes Technologies (OSE: AZT) reported total revenues of NOK 26.4 million and an EBITDA of NOK 2.7 million for the fourth quarter of 2024.Financial Highlights: · Total revenue for Q4 2024 was NOK 26.4 million, compared to NOK 29.1 million in Q4 2023. 2024 12M revenue totals NOK 108.1 million (12M 2023: NOK 119.7 million). · EBITDA for the quarter came in at NOK 2.7 million (Q4 2023: NOK 1.9 million), with a profit before tax of NOK 5.1 million. 12M 2024  EBITDA stands at NOK 5.3 million (12M 2023: NOK 22.1 million), and profit before tax

Long-Term Incentive Plan - grant of share options to primary insiders

Tromsø, Norway, 18 December 2024 - The Board of Directors in ArcticZymes Technologies ASA (the "Company") has decided to grant 335,000 share options to senior management under the Company's long-term incentive plan.The strike price of the options are NOK 15.00 per share.The options will have 12 months waiting period, 36 months vesting period and 12 months exercise period. The options are granted in accordance with the Company's guidelines for remuneration to senior management approved by the Annual General Meeting on 20 May 2021. The following primary insiders have been granted options:

ArcticZymes Expands SAN HQ Portfolio with Two Advanced Solutions Tailored for Cell, Gene and Vaccine Biomanufacturers

Tromsø, Norway, December 9, 2024 – ArcticZymes Technologies (OSE:AZT) introduces two cutting-edge products, SAN HQ ELISA SensoPlus and SAN HQ GMP neo, designed specifically to meet the evolving demands of the cell, gene and vaccine biomanufacturing sector.The new SAN HQ ELISA SensoPlus represents a next-generation innovation for detecting trace amounts of SAN HQ nucleases during therapeutic manufacturing processes. With over a fivefold increase in sensitivity compared to its predecessor, this ELISA kit ensures precise monitoring while offering significant workflow benefits. Features such as

ArcticZymes' M-SAN HQ Sets New Standard for Measles Virus Purification with Unmatched DNA Clearance and High Recovery Rates

Tromsø, Norway – November 21, 2024 – ArcticZymes Technologies ASA (OSE: AZT), is proud to highlight the exceptional performance of our M-SAN HQ nuclease in the purification of recombinant measles viruses (MV), as detailed in a recent publication in the Journal of Chromatography A. The study demonstrates how integrating M-SAN HQ nuclease with heparin affinity chromatography streamlines MV purification, achieving unmatched levels of both purity and yield.Innovative Approach to MV Purification The study, titled "Highly Pure Measles Virus Generated by Combination of Salt-Active Nuclease

rcticZymes Technologies - Primary insider trading

(Tromsø 11 November 2024) Olav Lanes,  VP R&D and applications has on 11 November purchased 5.000 shares in ArcticZymes Technologies ASA for NOK 13,90 per share. Following this transaction holds Mr. Lanes 7.000 shares and 100.000 options in the company.Marit Sjo Lorentzen, VP Operations has on 11 November purchased 5.000 shares in ArcticZymes Technoloiges ASA for NOK 13.88 per share. Following this transaction holds Mrs. Lorentzen 25.331 shares and 100,000 options in the company. This information is subject to the disclosure requirements in articles 19 of the Regulation EU 596/2014 (the

ArcticZymes Technologies - Primary insider trading

(Tromsø 08 November 2024) Frank Mathias, Chairman of the Board has on 07 November purchased 2.000 shares in ArcticZymes Technologies ASA for EUR 1.194 per share. Following this transaction holds Mr. Mathias 9.000 shares in the company.This information is subject to the disclosure requirements in articles 19 of the Regulation EU 596/2014 (the EU Market Abuse Regulation) and section 5-12 of the Norwegian Securities Trading Act. For additional information, please contactBørge SørvollCFO+4795290187ir@arcticzymes.com About ArcticZymes Technologies ASA ArcticZymes Technologies is

ArcticZymes Technologies - Primary insider trading

(Tromsø 07 November 2024) Michael Akoh, CEO has on 07 November purchased 7.660 shares in ArcticZymes Technologies ASA for NOK 13.26 per share. Following this transaction holds Mr. Akoh 7.660 shares and 200.000 options in the company.Sharon Brownlow,  Board member has on 7 November purchased 10.570 shares in ArcticZymes Technoloiges ASA for GBP 0.9378 per share. Following this transaction holds Mrs. Brownlow 10.570 shares in the company. This information is subject to the disclosure requirements in articles 19 of the Regulation EU 596/2014 (the EU Market Abuse Regulation) and section 5-12

ArcticZymes Technologies - Primary insider trading

(Tromsø 06 November 2024) Frank Mathias, Chairman of the Board has on 06 November purchased 7.000 shares in ArcticZymes Technologies ASA for EUR 1.242 per share. Following this transaction holds Mr. Mathias 7.000 shares in the company.Børge Sørvoll, CFO has on 6 November purchased 5.000 shares in ArcticZymes Technoloiges ASA for NOK 14.00 per share. Following this transaction holds Mr. Sørvoll 100.428 shares and 280,000 options in the company. This information is subject to the disclosure requirements in articles 19 of the Regulation EU 596/2014 (the EU Market Abuse Regulation) and

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe